Equities Analysts Issue Forecasts for Assembly Biosciences, Inc.’s Q1 2018 Earnings (ASMB)

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Stock analysts at William Blair issued their Q1 2018 EPS estimates for shares of Assembly Biosciences in a research note issued to investors on Monday. William Blair analyst Y. Xu anticipates that the biopharmaceutical company will earn ($0.96) per share for the quarter. William Blair also issued estimates for Assembly Biosciences’ Q2 2018 earnings at ($0.71) EPS, Q3 2018 earnings at ($0.74) EPS and Q4 2018 earnings at ($0.78) EPS.

ASMB has been the subject of several other research reports. Jefferies Group LLC started coverage on shares of Assembly Biosciences in a research note on Wednesday, November 8th. They issued a “buy” rating and a $50.00 target price for the company. Chardan Capital reiterated a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th. BidaskClub upgraded shares of Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th. Finally, Zacks Investment Research upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th.

WARNING: This piece of content was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/11/14/equities-analysts-issue-forecasts-for-assembly-biosciences-inc-s-q1-2018-earnings-asmb.html.

Assembly Biosciences (NASDAQ ASMB) opened at $33.34 on Tuesday. Assembly Biosciences has a 12 month low of $11.07 and a 12 month high of $36.31.

Hedge funds have recently added to or reduced their stakes in the company. Nationwide Fund Advisors bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $161,000. Parametric Portfolio Associates LLC boosted its position in shares of Assembly Biosciences by 13.6% in the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 1,203 shares during the period. Legal & General Group Plc bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $212,000. Wells Fargo & Company MN bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $213,000. Finally, Trexquant Investment LP bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $217,000. Institutional investors own 62.19% of the company’s stock.

In other news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $29.55, for a total value of $29,550.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.60% of the stock is currently owned by company insiders.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply